| Project/Area Number |
18K08371
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 54010:Hematology and medical oncology-related
|
|---|
| Research Institution | Kitasato University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2018-04-01 – 2021-03-31
|
| Project Status |
Completed (Fiscal Year 2020)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2020: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2019: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2018: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | CD109 / 造血分化 / 骨髄造血 / TGFb / TGFbシグナル / トランスフォーミング成長因子 |
|---|
| Outline of Final Research Achievements |
CD109 is a negative regulator for TGFb which is a key regulatory molecule for hematopoiesis and oncogenesis. In the research, we analyzed biological function of CD109 using knockout mice. We found that CD109 was expressed in mature B cells, and in the knockout mice, plasmablasts in the spleen showed tendency of decrease. Of note, expression of CD109 was not observed in the murine bone marrow cells, which was a major difference between human and mice. We also analyzed the value of serum soluble CD109 in healthy volunteers and patients with hematological disorders. The result showed that soluble CD109 had a tendency of increase in patients with immune thrombocytopenia (ITP), and soluble CD109 may be useful for the diagnosis and clinical follow-up for ITP.
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究は、造血器腫瘍・骨髄造血の制御因子であるTGFb分子に関わる研究であり、CD109分子についてマウス・ヒトにおける発現が明らかとなった。マウスにおいては骨髄細胞でCD109の発現が認められないことが明確となり、マウスで研究を行う場合には注意が必要であることが判明した。また、ヒト疾患との関連については、血清可溶性CD109の健常人における値が明らかになるとともに、免疫性血小板減少症で可溶性CD109が高値傾向になり、鑑別診断や病態把握に有用である可能性が明らかとなった。
|
